EZH2 and glioma: Moreover, in vivo studies verified MSC-derived exosomes’ ability loaded with miR-133b to inhibit glioma tumor growth, and MSC-derived exosomal miR-133b and the Wnt/β-catenin/EZH2 pathway could act as biomarkers for monitoring and prognosis in glioma therapy (106).